布地奈德混悬液吸入治疗中重度支气管哮喘的临床观察

目的评价中、重度支气管哮喘患者全身糖皮质激素治疗后吸人布地奈德混悬液减少全身糖皮质激素用量及时间。方法36例中、重度支气管哮喘患者为治疗组，给予吸人布地奈德混悬液2mgbid，对照组为同期收治的支气管哮喘患者33例。观察病情缓解和糖皮质激素减量的天数及肺功能变化。结果治疗组和对照组使用全身糖皮质激素天数分别为（7．6±2．7）、（12．8±3．7）d，症状缓解时间分别为（8．1±2．3）d和（12．5±3．1）d比较，差异均有统计学意义（P〈0．01）。结论中、重度支气管哮喘患者全身糖皮质激素治疗后吸人布地奈德混悬液减少全身糖皮质激素用量及时间，且不良反应少，无须再口服糖皮质激素。

Clinical Observation of Budesonide Inhalation for Treating Moderate and Severe Bronchia Asthma

[ ObJective] To evaluate the reduction of glucocorticoid dosage and period after systemically inhaling Budesonide among the moderate and severe asthma patients. [ Methods]36 moderate and severe bronchia asthma patients were taken as the case group treated with Budesonide （2rag, Bid） inhalation, 33 similar patients were taken as the control; observation was made on the patients ＂recovery and the reduction of glucocorticoid dosage and the patients＇lung faction changes. [ Results] The average systemic glucocorticoid intake periods in the case group and the control were （7.6 ± 2.7 ） days and （ 12.8 4 ±3.7 ） days respectively. [ Conclusion] Inhaling Budesonide after systemic glucocorticoid treatment could reduce the glucocorticoid dosage and period for the moderate and severe asthma patients, besides, it has no side effects and the necessity of oral glucocorticoid intake.